...
首页> 外文期刊>Heart rhythm: the official journal of the Heart Rhythm Society >Differential outcome of cardiac resynchronization therapy in ischemic cardiomyopathy and idiopathic dilated cardiomyopathy.
【24h】

Differential outcome of cardiac resynchronization therapy in ischemic cardiomyopathy and idiopathic dilated cardiomyopathy.

机译:缺血性心肌病和特发性扩张型心肌病心脏再同步治疗的差异结果。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Cardiac resynchronization therapy (CRT) is a therapy of proven benefit in patients with advanced heart failure. Identifying potential responders remains challenging, and whether the etiology of the heart failure is related to the potential hemodynamic benefit and long-term outcome of CRT is unclear. OBJECTIVE: The purpose of this study was to evaluate whether heart failure etiology (ischemic cardiomyopathy [ICM] vs nonischemic dilated cardiomyopathy [DCM]) was associated with CRT outcome and implantable cardioverter-defibrillator (ICD) shocks. METHODS: The study included 503 CRT recipients (CRT-D 90%) in a longitudinal CRT database: ICM (n = 312) and DCM (n = 191). Clinical variables and echocardiographic measures preimplant and postimplant were collected. Actuarial survival and ICD therapy data were assessed with Kaplan-Meier curve and log rank tests. RESULTS: Pre-CRT, ICM patients were older and had higher creatinine levels (P <.001). At median follow-up of 7.1 months, the DCM group experienced greater improvement in left ventricular ejection fraction (8.3% +/- 10% vs 6.2% +/- 10%, P = .05) and left ventricular end-diastolic volumes than did those with ICM (-28%.4 +/- 53 mL vs -15.3 +/- 46 mL, P = .024). Survival estimates at 4 years were 55% for ICM and 77% for DCM groups (P <.001), respectively, whereas no significant difference in the incidence of appropriate/inappropriate ICD shocks was observed. The ICM group remained at higher risk for death compared to the DCM group after controlling for preimplant variables (hazard ratio 1.6, 95% confidence interval 1.1-2.3, P = .008). CONCLUSION: In response to CRT and in contrast to ICM, DCM patients experienced greater improvement in left ventricular systolic function and reverse remodeling while also sustaining a greater survival benefit.
机译:背景:心脏再同步治疗(CRT)是一种对晚期心力衰竭患者证明有效的治疗方法。确定潜在的反应者仍然具有挑战性,尚不清楚心力衰竭的病因是否与潜在的血液动力学益处和CRT的长期结果相关。目的:本研究的目的是评估心力衰竭病因(缺血性心肌病[ICM]与非缺血性扩张型心肌病[DCM])是否与CRT结局和植入式心脏复律除颤器(ICD)休克相关。方法:该研究在纵向CRT数据库中包括503位CRT接受者(CRT-D 90%):ICM(n = 312)和DCM(n = 191)。收集植入前和植入后的临床变量和超声心动图测量。用Kaplan-Meier曲线和对数秩检验评估精算生存率和ICD治疗数据。结果:CRT前,ICM患者年龄较大,肌酐水平较高(P <.001)。在中位随访7.1个月时,DCM组的左心室射血分数(8.3%+/- 10%对6.2%+/- 10%,P = .05)和左心室舒张末期容积的改善大于那些使用ICM的患者(-28%.4 +/- 53 mL对-15.3 +/- 46 mL,P = .024)。 ICM组4年生存率分别为55%和DCM组77%(P <.001),而适当/不合适的ICD休克发生率没有显着差异。在控制植入前变量后,ICM组的死亡风险比DCM组高(危险比1.6,95%置信区间1.1-2.3,P = .008)。结论:响应CRT并与ICM相反,DCM患者的左心室收缩功能和逆重塑改善更大,同时还具有更大的生存获益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号